Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Debt to Equity (2019 - 2025)

BridgeBio Pharma's Debt to Equity history spans 7 years, with the latest figure at -$0.27 for Q4 2025.

  • For Q4 2025, Debt to Equity rose 27.15% year-over-year to -$0.27; the TTM value through Dec 2025 reached -$0.27, up 27.15%, while the annual FY2025 figure was -$0.27, 27.15% up from the prior year.
  • Debt to Equity for Q4 2025 was -$0.27 at BridgeBio Pharma, up from -$0.37 in the prior quarter.
  • Across five years, Debt to Equity topped out at -$0.14 in Q3 2021 and bottomed at -$0.5 in Q4 2021.
  • The 5-year median for Debt to Equity is -$0.36 (2023), against an average of -$0.34.
  • The largest annual shift saw Debt to Equity crashed 217.81% in 2021 before it skyrocketed 30.23% in 2022.
  • A 5-year view of Debt to Equity shows it stood at -$0.5 in 2021, then skyrocketed by 30.23% to -$0.35 in 2022, then grew by 4.1% to -$0.33 in 2023, then decreased by 11.72% to -$0.37 in 2024, then increased by 27.15% to -$0.27 in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Debt to Equity are -$0.27 (Q4 2025), -$0.37 (Q4 2024), and -$0.36 (Q3 2024).